Published online before print May 21, 2009

This Article Full Text (Rapid PDF) All Versions of this Article: jmoldx.2009.090047v1 11/4/279    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Potter, N. T. Search for Related Content PubMed PubMed Citation Articles by Potter, N. T. Related Collections Related Article

Copyright © 2009 American Society for Investigative Pathology
Journal of Molecular Diagnostics, doi:10.2353/jmoldx.2009.090047

Accepted for publication March 30, 2009.

Commentary

You Can Build It . . . . . . . . . But Will They Come? The Potential "Expansion" of Testing Methodologies for Fragile X Syndrome

From Molecular Pathology Laboratory Network, Inc., Maryville TN and the Department of Pathology, University of Tennessee Medical Center, Knoxville TN

^@ To whom correspondence should be addressed. E-mail: npotter{at}mplnet.com.

	Abstract

This Commentary highlights a brief technical report by Iwashi and colleagues (J Mol Diagn 11: JMD08-0118) that describes an enhancement to an antibody-based ELISA assay for the detection of the FMR1 protein (FMRP) in peripheral blood.